The results were consistent with the current guidelines advocating treatment and the use of prophylactic and/or therapeutic anticoagulants in patients with COVID-19 appeared to be advocated.[10,11,41] According to the current studies, mechanism of anticoagulant therapy in reduction of thrombosis events among COVID-19 patients might be as follows.[42,43] After infection caused by SARS-CoV-2, the virus would attack angiotensin converting enzyme 2 (ACE2) and decrease its content, making the role of ACE2 from angiotensin II to angiotensin 1 and 7. The gene discussed is ACE2; the disease is COVID-19.